Efgartigimod as follow-up treatment for generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have generalized myasthenia gravis and were hospitalized for a severe flare-up (myasthenic crisis).
- You have antibodies against AChR in your blood.
- You have already completed one round of efgartigimod treatment (4 weekly infusions) and had at least a 2-point improvement in daily activity scores.
- You have not received certain other MG treatments like IVIg, plasma exchange, or high-dose steroids within the last month.
- You have not had thymectomy surgery in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.